DZ Bank’s Standard BioTools LAB Stock Holding History

DZ Bank’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-348	Closed	-$208K	–	981
2018 Q1	$208K	Buy	+348	New	+$2.29K	﹤0.01%	929

Other funds holding LAB

LCS

Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HVC

Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

DZ Bank's LAB Position: Q2 2018 in Review

DZ Bank sold out of Standard BioTools (LAB) in Q2 2018, closing a stake of 348 shares — an estimated $208K sold.

DZ Bank first reported a position in LAB in Q1 2018 and held it in 1 quarter. The position peaked at $208K in Q1 2018. 84 funds tracked by Wall St. Rank hold LAB as of Q2 2018.

DZ Bank reported no remaining Standard BioTools position as of Q2 2018 after selling out during the quarter.
DZ Bank sold 348 Standard BioTools shares in Q2 2018, an estimated $208K.
DZ Bank first reported a position in Standard BioTools in Q1 2018 and held it in 1 quarter.
DZ Bank's Standard BioTools position peaked at $208K in Q1 2018.
84 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2018.

Based on DZ Bank's 13F filing for Q2 2018, filed 14 Aug 2018.